Kymathera added $80 million in a series B round to advance its PI3Kα inhibitor K-1728 into clinical development. The next-generation drug has better selectivity for mutant PI3Kα over wild-type protein compared to current PI3Kα inhibitors, increasing the therapeutic window and potentially making K-1728 more potent with less hyperglycemia.
Bioworld
Original source
Rise launches its research-backed feature in three languages across the UAE and MENA
Phys.orgSee more headlines and perspectives on Google News
"I may sound arrogant, but I had thought I would not get complaints if I won," the Japanese scientist said of his achievement.
OCI will conduct joint semiconductor materials R&D with Jeonbuk National University, which is investing 64.2 billion won in a shared testbed.
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer